Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial

Identificador:  imarina:9373510

Handle: https://hdl.handle.net/20.500.11797/imarina9373510

Autores:  Evangelista, A; Galian-Gay, L; Guala, A; Teixido-Tura, G; Calvo-Iglesias, F; Sevilla, T; Bermejo, J; Méndez, I; Sánchez, V; Carmona, JMR; Alegret, JM; Ferrer-Sistach, E; Saura, D; Ruiz-Muñoz, A; Dux-Santoy, L; Carmona, MA; Huguet, M; Cuellar-Calabria, H; Sao-Aviles, A; Ferreira-González, I; Rodríguez-Palomares, JF

Resumen:
BACKGROUND: Ascending aorta dilation and aortic valve degeneration are common complications in patients with bicuspid aortic valve. Several retrospective studies have suggested the benefit of statins in reducing these complications. This study aimed to determine whether atorvastatin treatment is effective in reducing the growth of aortic diameters in bicuspid aortic valve and if it slows the progression of valve calcification. METHODS: In a randomized clinical trial, 220 patients with bicuspid aortic valve (43 women; 46 +/- 13 years of age) were included and treated with either 20 mg of atorvastatin per day or placebo for 3 years. Inclusion criteria were >= 18 years of age, nonsevere valvular dysfunction, nonsevere valve calcification, and ascending aorta diameter